GlassScriptPhysician profile
Gary Siegel
NPI 1952398778
$23,986.23
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $809 · 2021: $874 · 2022: $1,025 · 2023: $145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $145.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $15,926.89 | 2019-2023 | Tavneos, Enbrel, Prolia |
| Pfizer INC. | $4,904.18 | 2019-2022 | |
| Abbvie INC. | $695.23 | 2019-2023 | Rinvoq |
| Glaxosmithkline, LLC. | $537.51 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $314.99 | 2019-2022 | |
| Genentech USA, INC. | $251.07 | 2019 | |
| Lilly USA, LLC | $208.53 | 2019-2022 | |
| Janssen Biotech, INC. | $192.11 | 2019-2022 | |
| Celgene Corporation | $185.96 | 2019 | |
| Radius Health, INC. | $164.74 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $93.97 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $79.69 | 2019 | |
| Horizon Therapeutics Plc | $75.02 | 2022-2023 | Krystexxa |
| Ucb, INC. | $72.53 | 2019-2022 | |
| Aurinia Pharma U.S., INC. | $52.52 | 2021-2023 | Lupkynis |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $51.29 | 2019 | |
| Ferring Pharmaceuticals INC. | $31.86 | 2019 | |
| Hikma Pharmaceuticals USA | $27.49 | 2019 | |
| Mallinckrodt Hospital Products INC. | $24.53 | 2023 | Acthar |
| Pacira Therapeutics, INC. | $24.10 | 2019 | |
| Organon LLC | $23.29 | 2022 | |
| Fidia Pharma USA INC. | $16.90 | 2020 | |
| Pharming Healthcare, INC. | $16.84 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $14.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Siegel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.